味の素（2802.T）发布 FY2026Q1 业绩并上调全年指引，功能性材料旺盛提振预期

Iran talks in focus; Sandisk, Block earnings - what’s moving markets
Introduction & Market Context
Ajinomoto Co., Inc. (TYO:2802) presented its first-quarter fiscal 2026 results on August 6, 2026, showcasing record-breaking performance across key financial metrics while raising full-year guidance. Despite the strong operational results, shares declined 2.57% to ¥5,196 in after-hours trading, suggesting investor focus on rising cost pressures and execution risks ahead.
The Japanese food and chemicals giant reported sales of ¥412.1 billion, business profit of ¥60.1 billion, and profit attributable to owners of ¥36.4 billion—all representing new quarterly records. The company’s business profit surged 127% year-over-year, driven primarily by exceptional growth in its Functional Materials segment and steady gains across its core Seasonings and Foods business.
Quarterly Performance Highlights
The first quarter of fiscal 2026 marked Ajinomoto’s strongest quarterly performance on record, as illustrated in the company’s financial summary. Sales reached ¥412.1 billion, representing 113% of the prior year period, with organic growth of 105% excluding currency translation effects. Business profit of ¥60.1 billion exceeded the prior year by 27%, while profit attributable to owners grew 13% to ¥36.4 billion.
The company’s profit growth was driven by multiple factors, as detailed in the following breakdown of business profit evolution. Gross profit increased by ¥25.6 billion through a combination of higher sales volumes (¥18.4 billion) and improved margins (¥7.2 billion). However, these gains were partially offset by ¥12.3 billion in strategic investments across personnel, marketing, and research and development.
Segment performance varied considerably, with the Healthcare and Others division delivering the largest profit contribution. As shown in the segment analysis below, Healthcare and Others added ¥9.7 billion in business profit during Q1, while Seasonings and Foods contributed ¥4.7 billion. Frozen Foods experienced a slight decline of ¥0.6 billion due to higher raw material and logistics costs.
Functional Materials Drives Growth Engine
The standout performer in Q1 was the Functional Materials business within the Healthcare and Others segment, which delivered exceptional results driven by strong demand for ABF™ (Ajinomoto Build-up Film) used in high-performance boards for AI applications, servers, and network infrastructure.
According to the presentation, Functional Materials achieved sales growth of 154% year-over-year and business profit growth of 177% in the first quarter. This performance significantly exceeded initial expectations and prompted management to revise full-year forecasts upward by ¥9.0 billion in sales and ¥5.0 billion in business profit for the Healthcare and Others segment.
The company attributed the strong performance primarily to product mix improvements rather than price increases, with demand for high-value ABF products remaining robust. Management indicated that sales momentum continued into the July-September period, supporting the upward revision to full-year guidance.
To further capitalize on this growth trajectory, Ajinomoto announced plans to merge Ajinomoto Fine-Techno Co., Inc., the core entity of its Functional Materials business, into the parent company effective April 1, 2027. The absorption-type merger aims to enhance competitiveness and accelerate achievement of the company’s 2030 Roadmap targets.
Revised Full-Year Outlook
Based on first-quarter momentum, Ajinomoto raised its fiscal 2026 forecasts across all key metrics. The revised guidance calls for sales of ¥1,732.0 billion (up ¥9.0 billion from initial forecast), business profit of ¥202.0 billion (up ¥5.0 billion), and profit attributable to owners of ¥123.5 billion (up ¥3.5 billion).
The upward revision reflects strong performance in Functional Materials and assumes continued execution across all business segments. The forecast incorporates an exchange rate assumption of ¥150 per U.S. dollar and anticipates organic growth of approximately 10% for the full year, compared to 3.7% achieved in fiscal 2025.
The following segment breakdown illustrates how the revised forecast compares to both the initial plan and prior year actuals, with Healthcare and Others accounting for the entire ¥5.0 billion upward revision in business profit.
Middle East Cost Pressures and Mitigation Strategy
A significant challenge highlighted in the presentation involves rising costs stemming from Middle East tensions. Management estimates a potential ¥25.0 billion negative impact on business profit for fiscal 2026, based on assumptions of Dubai crude oil at $110 per barrel and an exchange rate of ¥158 per U.S. dollar.
The cost increases are expected to affect multiple areas including fermentation raw materials, food ingredients, packaging materials, energy costs, and logistics. Executive Officer Masataka Kaji emphasized the company’s commitment to absorbing this impact through "wide-ranging and solid cost reduction initiatives" and "agile pricing measures in line with market conditions."
The timeline for addressing these cost pressures varies by business segment. In the Food Products business, management expects the full impact of increased costs to become apparent from the second quarter onward, as illustrated in the quarterly mitigation plan below.
The company projects a challenging second quarter where cost increases will significantly outweigh mitigation efforts, followed by a strong recovery in the second half as pricing actions and cost reductions take full effect. This approach requires careful execution to avoid demand destruction while maintaining profitability targets.
Segment-Level Performance Analysis
The comprehensive segment metrics presented by management reveal divergent performance trajectories across Ajinomoto’s portfolio. The Healthcare and Others segment demonstrated the strongest momentum with organic growth of 15.7% in Q1 and a projected 19% for the full year, while maintaining industry-leading EBITDA margins of 32.6% in the quarter.
The Seasonings and Foods business, representing the company’s largest segment, achieved more modest but steady growth with organic expansion of 4.1% in Q1 and a projected 7% for fiscal 2026. Return on invested capital (ROIC) for this segment remained strong at approximately 19%, well above the 8% weighted average cost of capital.
Frozen Foods presents a more challenging picture, with Q1 organic growth declining 1.6% due to cost pressures, though management projects a recovery to approximately 7% growth for the full year. This segment’s ROIC of approximately 5% remains below its 5% cost of capital, indicating ongoing profitability challenges that require operational improvements.
Strategic Initiatives and 2030 Roadmap
CEO Shigeo Nakamura emphasized the company’s commitment to achieving its 2030 Roadmap targets ahead of schedule, building on the strong first-quarter momentum. The strategic priorities include enhancing human resource and organizational capabilities, evolving ASV (Ajinomoto Group Creating Shared Value) initiatives, and maintaining disciplined investment in growth opportunities.
The planned merger of Ajinomoto Fine-Techno represents a key structural initiative designed to strengthen the company’s position in electronic materials and functional chemicals. With fiscal 2025 sales of ¥98.4 billion and operating profit of ¥53.0 billion, Fine-Techno contributes meaningfully to group results and represents a core growth platform.
In the Bio-Pharma Services (CDMO) business, management highlighted progress across multiple platforms including small molecules in Europe, AJIPHASE® in Japan, and gene therapy through Forge in North America. While AJIPHASE® revenue declined in Q1 due to shipment timing, results remained in line with internal plans, and management expects increased contributions in the third quarter.
Market Reaction and Valuation Considerations
Despite the strong operational performance, Ajinomoto shares declined 2.57% following the presentation, closing at ¥5,196. The stock has delivered a remarkable 61.6% return year-to-date but remains 18.7% below its 52-week high of ¥6,340, suggesting some profit-taking may be occurring.
The complete financial statements reveal year-to-date progress of 29% toward full-year business profit targets, indicating the company is slightly ahead of a linear quarterly run rate.
According to InvestingPro analysis, the stock trades at a P/E ratio of 37.79 with a PEG ratio of 0.38, suggesting relatively attractive valuation relative to near-term earnings growth despite concerns about absolute valuation levels. The company’s return on equity of 18% over the last twelve months demonstrates strong capital efficiency, though investors appear focused on the execution risks associated with absorbing ¥25.0 billion in Middle East-related cost increases.
The market’s cautious response may reflect concerns about the company’s ability to implement pricing actions without dampening demand, particularly in consumer-facing businesses where competitive dynamics and inflation sensitivity could limit pricing power. Additionally, the concentration of growth in Functional Materials—a cyclical business tied to semiconductor and electronics demand—may raise questions about sustainability of current momentum.
Management’s confidence in achieving revised targets while absorbing significant cost headwinds will be tested in coming quarters, with second-quarter results likely providing crucial validation of the mitigation strategy outlined in the presentation.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.